Hesse LM et al: Clinically important drug interactions with zopiclone, zolpidem and zaleplon. CNS Drugs 2003;17:513.
Jacobson LH et al: Suvorexant for the treatment of insomnia. Exp Rev Clin Pharmacol 2014;7:711.
Kato K et al: Neurochemical properties of ramelteon, a selective MT1/MT2 receptor agonist. Neuropharmacology 2005;48:301.
Kralic JE et al: GABA(A) receptor alpha-1 subunit deletion alters receptor subtype assembly, pharmacological and behavioral responses to benzodiazepines and zolpidem. Neuropharmacology 2002;43:685.
Krystal AD: The changing perspective of chronic insomnia management. J Clin Psychiatry 2004;65(Suppl 8):20.
Lader M, Tylee A, Donoghue J: Withdrawing benzodiazepines in primary care. CNS Drugs 2009;23:2319.
McKernan RM et al: Anxiolytic-like action of diazepam: Which GABA(A) receptor subtype is involved? Trends Pharmacol Sci 2001;22:402.
Morairty SR, et al: The hypocretin/orexin antagonist almorexant promotes sleep without impairment of performance in rats. Front Neurosci 2014;8:3.
Neubauer DN: New directions in the pharmacologic treatment of insomnia. Primary Psychiatry 2006;13:51.
Rapaport MJ et al: Benzodiazepine use and driving: A meta analysis. J Clin Psychiatry 2009;70:663.
Rosenberg R et al: An assessment of the efficacy and safety of eszopiclone in the treatment of transient insomnia in healthy adults. Sleep Med 2005;6:15.
Sanger DJ: The pharmacology and mechanism of action of new generation, nonbenzodiazepine hypnotic agents. CNS Drugs 2004;18(Suppl 1):9.
Silber MH: Chronic insomnia. N Engl J Med 2005;353:803.
Walsh JK: Pharmacologic management of insomnia. J Clin Psychiatry 2004;65(Suppl 16):41.
Winkelman JW: Insomnia disorder. N Engl J Med 2015;373:1437.
Wurtman R: Ramelteon: A novel treatment for the treatment of insomnia. Expert Rev Neurother 2006;6:957.
As described in this chapter, nonpharmacologic factors are very important in the management of sleep problems: proper diet (and avoidance of snacks before bedtime), exercise, and a regular time and place for sleep. Avoidance of stimulants is very important, and the large intake of diet colas reported by the patient should be reduced, especially in the latter half of the day. If problems persist after these measures are implemented, one of the newer hypnotics (eszopiclone, zaleplon, or zolpidem) may be tried on a short-term basis.
Anthony J. Trevor, PhD*
The Alcohols